OTC: BDPT
BIOADAPTIVES, INC.CIK 0001575142 · SIC 2834 · Pharmaceutical Preparations
Every 8-K is open in full. Other 10-Ks and 10-Qs show a 3-bullet preview. A free account reads 3 more full reports a month. Generating a report requires a verified account.
Sign up freeWant to see a complete report first? Today's free report (COTY 10-K) is open in full — no account needed.
Summary not yet generated.
Summary not yet generated.
Partner
Trade BDPT commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Latest financial statements
From 10-Q filed Aug 19, 2026 (period ending Jun 30, 2026). As printed on the EDGAR/iXBRL face — not generated by the model.
Consolidated Statements of Operations and Comprehensive Loss (Unaudited)
| Description | Three months June 30, 2026 | Three months June 30, 2025 | Six months June 30, 2026 | Six months June 30, 2025 |
|---|---|---|---|---|
| Revenues | 4,988 | 3,219 | 10,502 | 3,219 |
| Cost of revenue | 748 | 2,156 | 2,149 | 2,156 |
| Gross Profit | 4,240 | 1,063 | 8,353 | 1,063 |
| Operating Expenses | ||||
| General and administrative | 177,745 | 197,892 | 358,795 | 341,275 |
| Professional fees | 22,171 | 81,390 | 41,952 | 187,155 |
| Impairment of inventory | - | - | - | - |
| Depreciation | 1,500 | 1,000 | 3,000 | 1,000 |
| Total Operating Expenses | 201,416 | 280,282 | 403,747 | 529,430 |
| Loss from operations | (197,176) | (279,219) | (395,394) | (528,367) |
| Other Income (Expense) | ||||
| Other income | - | - | 5 | - |
| Interest expense | (115,038) | (9,649) | (202,795) | (19,296) |
| Change in fair value of derivative liabilities | 446,730 | 130,954 | 621,614 | 192,613 |
| Gain on settlement of debt | 15,574 | - | 15,574 | - |
| Total Other Income | 347,266 | 121,305 | 434,398 | 173,317 |
| Income (loss) before income taxes | 150,090 | (157,914) | 39,004 | (355,050) |
| Net Income (Loss) | 150,090 | (157,914) | 39,004 | (355,050) |
| Net Income (Loss) Per Common Share: | ||||
| Basic | 0.01 | (0.02) | 0.00 | (0.04) |
| Diluted | (0.00) | (0.02) | (0.00) | (0.04) |
| Weighted Average Number of Common Shares Outstanding: | ||||
| Basic and Diluted | 14,192,536 | 9,533,375 | 13,106,785 | 8,998,067 |
Consolidated Balance Sheets (Unaudited)
| Description | June 30, 2026 | December 31, 2025 |
|---|---|---|
| ASSETS | ||
| Current Assets: | ||
| Cash | 29,221 | 158,445 |
| Inventory | 36,046 | 44,706 |
| Security deposit | - | 2,500 |
| Prepaid expense | 2,500 | 6,250 |
| Total Current Assets | 67,767 | 211,901 |
| Property and equipment, net | 11,000 | 14,000 |
| TOTAL ASSETS | 78,767 | 225,901 |
| LIABILITIES AND STOCKHOLDERS' DEFICIT | ||
| Current Liabilities: | ||
| Accounts payable and accrued liabilities | 268,774 | 232,725 |
| Derivative liabilities | 1,050,397 | 1,738,804 |
| Convertible notes | 490,629 | 352,332 |
| Notes Payable | 32,096 | 32,096 |
| Due to related party | 2,978 | - |
| Total Current Liabilities | 1,844,874 | 2,355,957 |
| Total Liabilities | 1,844,874 | 2,355,957 |
| Stockholders' Deficit: | ||
| Preferred stock, ($.0001 par value, 31,000,000 shares authorized; | ||
| Series A Preferred Stock 4,000,000 shares designated; 11,167 issued and outstanding as of June 30, 2026 and December 31, 2025 | 1 | 1 |
| Series B Preferred Stock 5,000,000 shares designated; 9,667 share issued and outstanding as of June 30, 2026 and December 31, 2025 | 1 | 1 |
| Series C Preferred Stock 1,000,000 shares designated; 1,000,000 share issued and outstanding as of June 30, 2026 and December 31, 2025 | 100 | 100 |
| Series D Preferred Stock 20,000,000 shares designated; 362,393 and 198,335 share issued and outstanding as of June 30, 2026 and December 31, 2025, respectively | 36 | 20 |
| Common stock ($.0001 par value, 1,250,000,000 shares authorized; 36,595,174 and 12,008,725 shares issued and outstanding as of June 30, 2026 and December 31, 2025, and 66 issuable, respectively) | 3,659 | 1,200 |
| Additional paid-in capital | 8,918,181 | 8,595,711 |
| Subscription receivable | (5,885) | (5,885) |
| Accumulated deficit | (10,682,200) | (10,721,204) |
| Total Stockholders' Deficit | (1,766,107) | (2,130,056) |
| TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT | 78,767 | 225,901 |
Consolidated Statements of Cash Flows (Unaudited)
| Description | Six months ended Jun 30, 2026 | Six months ended Jun 30, 2025 |
|---|---|---|
| Operating Activities: | ||
| Net cash from operating activities | (129,224) | (208,888) |
| Investing Activities: | ||
| Net cash from investing activities | — | (18,000) |
| Financing Activities: | ||
| Net cash from financing activities | — | 300,000 |
| Net increase/(decrease) in cash | (129,224) | 73,112 |
Amounts in USD as reported; EPS as reported. Statements found on the EDGAR/iXBRL face print as filed; the rest are presentation-friendly mappings of filer XBRL tags. Use EDGAR for interactive notes and detail. Interactive statements & notes on EDGAR ↗